France· FR:68772407
FIASP 100 unités/ml, solution injectable en flacon
A medicinal product containing insuline asparte, registered in France by NOVO NORDISK (DANEMARK), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- INSULINE ASPARTE
- Manufacturer
- NOVO NORDISK (DANEMARK)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009300831781 flacon(s) en verre de 10 mlEUR 15.82
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insuline asparte in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaDAZPARDAGan & Lee Pharmaceuticals Europe GmbH, Düsseldorf
- United KingdomFiasp 100units/ml solution for injection 10ml vialsNovo Nordisk Ltd
- United States.Insulin Aspart Protamine and Insulin AspartA-S Medication Solutions
- BelgiumDazparda 100 U/mlGan & Lee Pharmaceuticals Europe
- FinlandDazpardaGan & Lee Pharmaceuticals Europe GmbH
- SwedenDazparda 100 E/ml Injektionsvätska, lösning i förfylld injektionspennaGan & Lee Pharmaceuticals Europe GmbH
- IcelandFiaspNovo Nordisk A/S*
- PolandDazpardaGan & Lee Pharmaceuticals Europe GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Dazparda, Fiasp
- Liechtenstein · Dazparda, Insulin Aspart Sanofi
- Norway · Dazparda, Fiasp
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d600f985-0182-425e-a216-7ee47f408867 GET /v1/drugs/d600f985-0182-425e-a216-7ee47f408867?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68772407",
"date_amm": "2017-01-09",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/16/1160",
"substance": "INSULINE ASPARTE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "intraveineuse;sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about insuline asparte.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.